Fortress Biotech, INC Form 4 insider transactions

David Jin, CFO of Fortress Biotech, reports the acquisition and disposal of 500 shares of Series A Cumulative Perpetual Preferred Stock on July 10, 2024.

Fortress Biotech's CEO, Lindsay Rosenwald, recently acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock at a price of $7.3942 per share.

Fortress Biotech's CEO, Lindsay Rosenwald, acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock at a weighted average price of $7.3529 on July 8, 2024, bringing his total holdings to 117,500 shares.

Fortress Biotech's CEO, Lindsay A. Rosenwald, acquired 20,000 shares of common stock at a price of $1.6362 per share on June 28, 2024.

Fortress Biotech acquired 575,191 shares of Mustang Bio common stock as an equity fee following the closing of equity financings.

Fortress Biotech, a 10% owner of Journey Medical Corp, reports the transfer of 250,000 shares to employees as service grants between May 2022 and May 2023, decreasing its holdings.

Fortress Biotech's CEO, Lindsay A. Rosenwald, acquired 10,000 shares of common stock at $1.7589 per share on May 16, 2024, increasing his direct holdings to 2,873,905 shares.

Director Dov Klein of Fortress Biotech, Inc. (FBIO) acquired 10,000 shares of common stock at $1.89 per share on May 20, 2024.

Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 413,507 shares of common stock as an equity fee following the closing of an equity financing.

David Jin, CFO of Fortress Biotech, reports acquiring 2,352 shares of common stock under the company's Employee Stock Purchase Plan at a price of $1.7 per share.

Fortress Biotech, a 10% owner of Checkpoint Therapeutics, acquired 193,905 shares of common stock as an equity fee related to a financing consummated by Checkpoint.